QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life
Eshita Khera, Lekshmi Dharmarajan, Dominik Hainzl, Volker Engelhardt, Helena Vostiarova, John Davis, Nicolas Ebel, Kuno Wuersch, Vincent Romanet, Sherif Sharaby, Jeffrey D Kearns · 2024
Read QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life by Eshita Khera, Lekshmi Dharmarajan, Dominik Hainzl, Volker Engelhardt, Helena Vostiarova, John Davis, Nicolas Ebel, Kuno Wuersch, Vincent Romanet, Sherif Sharaby, Jeffrey D Kearns (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11652588.txt.
Description
Eshita Khera and co-authors model a cancer drug whose payload switches itself off in the blood. Antibody-drug conjugates join an antibody to a toxic payload by a linker. The drug here, DYP688, carries a signaling protein blocker that fades while riding the antibody, which makes its behavior hard to predict.
In their 2024 study, the team pairs a drug-level and tumor-growth model with a fine-grained model of drug action inside tumors. One combined exposure measure emerged as the driver of effect. Simulations show the drug works at its best despite the fleeting payload, defying the usual design rules. The model then carried the drug's behavior from animal tests to human forecasts with success.
Catalog record
| CREATOR | Eshita Khera, Lekshmi Dharmarajan, Dominik Hainzl, Volker Engelhardt, Helena Vostiarova, John Davis, Nicolas Ebel, Kuno Wuersch, Vincent Romanet, Sherif Sharaby, Jeffrey D Kearns |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |